Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Table 10

Change from baseline in eGFR over the 24-week follow-up period.

Time	Treatment group	Control group	Effect	F value	value
Pretreatment (ml/min/1.73 m^2)	44.04 ± 9.28	44.24 ± 8.75	Time effect	1.66	0.1422
Week 4 (ml/min/1.73 m^2)	47.91 ± 12.56	45.19 ± 11.11	Difference between groups	33.04	<0.0001
Week 8 (ml/min/1.73 m^2)	50.40 ± 13.73	44.69 ± 11.94
Week 12 (ml/min/1.73 m^2)	50.67 ± 13.48	45.66 ± 12.55
Week 16 (ml/min/1.73 m^2)	51.77 ± 13.85	44.41 ± 11.90
Week 20 (ml/min/1.73 m^2)	51.90 ± 13.68	44.39 ± 12.03
Week 24 (ml/min/1.73 m^2)	55.74 ± 50.82	44.46 ± 12.60